Prolonged Intravenous Therapy Versus Early Initiation of an Oral Loop Diuretic in Decompensated Heart Failure

Inclusion Criteria: Patient hospitalized due to exacerbation of heart failure symptoms, where AHF is the main cause of hospitalization. To be included in the study, all criteria 1 to 6 must be met: Fluid Retention Features: Described congestion above the lung fields on chest X-ray rales on chest auscultation Peripheral edema, yielding to pressure occurring within the limbs or the sacral part of the spine Increased pressure in the jugular veins (>=8 cm H2O) The concentration of natiuretic peptides must be assessed within 24 hours of admission to the hospital and be: ✔ NTpro-BNP >450 pg/mL for <55 years, 900 pg/mL for 55-75 years, and >1800 pg/mL for >75 years Exacerbation of heart failure treated with at least 40 mg of furosemide IV. (or 20 mg torasemide equivalent) Left ventricular ejection fraction < 50% (assessed and documented in the last 12 months prior to study entry) Age >= 18 years The study participant gave and signed an informed consent to participate in the study. No medical procedure related to the study was performed prior to giving informed consent. Exclusion Criteria: 1. Shortness of breath caused by respiratory infection, exacerbation of bronchial asthma, COPD 2. Body temperature > 38 C, signs of active infection requiring antibiotic therapy, sepsis, infective endocarditis 3. An episode of acute coronary syndrome, stroke or TIA within 6 months before randomization 4. Severe valvular disease requiring or in the process of qualifying for repair 5. Patients requiring dialysis (in the past, during hospitalization or in the process of qualifying for dialysis) 6. History of alcohol abuse in the last 2 years before randomization 7. Pregnancy or breastfeeding 8. Active cancer or in remission for less than 5 years